ZetaMet (Zeta-BC-003)

About Zetagen Therapeutics

Zetagen Therapeutics is a clinical-stage biotech focused on transforming the treatment of bone metastases and primary cancers through its proprietary Zeta Platform. The company's lead programs, ZetaMet and ZetaMAST, are in Phase 2a development for breast cancer bone metastases, with promising data showing complete responses and significant pain reduction. Backed by FDA Breakthrough Designations and a recent oversubscribed $12.9M Series B1 financing, Zetagen is advancing a novel treatment paradigm that combines anti-cancer, analgesic, and bone-regenerative effects in a single localized therapy.

Therapeutic Areas